Rapamycin-Eluting Coronary Stent for PCI: The TARGET IV Trial
A review of the TARGET IV trial evaluating the Firehawk rapamycin-eluting cobalt chromium coronary stent system. Can this new stent increase healing time, reduce adverse events, and eliminate the need for prolonged dual antiplatelet therapy?
By Christiana O. Oshotse, BA, and Robert W. Yeh, MD, MSc, MBA
